KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

AbbVie (ABBV) Shares Repurchased (2016 - 2026)

AbbVie has reported Shares Repurchased over the past 13 years, most recently at $3.0 million for Q4 2025.

  • Quarterly Shares Repurchased fell 99.16% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $980.0 million through Dec 2025, down 42.62% year-over-year, with the annual reading at $980.0 million for FY2025, 42.62% down from the prior year.
  • Shares Repurchased was $3.0 million for Q4 2025 at AbbVie, down from $4.0 million in the prior quarter.
  • Over five years, Shares Repurchased peaked at $2.0 billion in Q1 2023 and troughed at $3.0 million in Q4 2023.
  • The 5-year median for Shares Repurchased is $10.0 million (2021), against an average of $354.0 million.
  • Year-over-year, Shares Repurchased surged 11833.33% in 2024 and then plummeted 99.16% in 2025.
  • A 5-year view of Shares Repurchased shows it stood at $131.0 million in 2021, then plummeted by 96.95% to $4.0 million in 2022, then fell by 25.0% to $3.0 million in 2023, then surged by 11833.33% to $358.0 million in 2024, then plummeted by 99.16% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Shares Repurchased are $3.0 million (Q4 2025), $4.0 million (Q3 2025), and $12.0 million (Q2 2025).